stoxline Quote Chart Rank Option Currency Glossary
NovaBay Pharmaceuticals, Inc. (NBY)
2.57  -0.28 (-9.82%)    06-13 16:00
Open: 2.78
High: 2.8
Volume: 145,767
Pre. Close: 2.85
Low: 2.55
Market Cap: 3(M)
Technical analysis
2024-06-13 4:45:05 PM
Short term     
Mid term     
Targets 6-month :  7.7 1-year :  10.62
Resists First :  6.59 Second :  9.1
Pivot price 3.49
Supports First :  2.55 Second :  2.12
MAs MA(5) :  2.74 MA(20) :  3.81
MA(100) :  4.16 MA(250) :  11.52
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  2 D(3) :  1.9
RSI RSI(14): 39.9
52-week High :  44.79 Low :  2.45
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NBY ] has closed above bottom band by 25.7%. Bollinger Bands are 110.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.8 - 2.81 2.81 - 2.82
Low: 2.51 - 2.53 2.53 - 2.55
Close: 2.55 - 2.57 2.57 - 2.59
Company Description

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Headline News

Mon, 10 Jun 2024
NovaBay Pharmaceuticals Plan of Compliance Is Accepted by the NYSE American - Vision Monday

Thu, 06 Jun 2024
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Share Price Passes Above 50 Day Moving Average of $0.00 - Defense World

Tue, 04 Jun 2024
NOVABAY PHARMACEUTICALS INC Trade Ideas — GETTEX:B9P0 — TradingView - TradingView

Thu, 30 May 2024
Why Is NovaBay Pharmaceuticals (NBY) Stock Down 39% Today? - InvestorPlace

Wed, 29 May 2024
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and ... - Business Wire

Mon, 20 May 2024
NovaBay Pharmaceuticals Stock Is Up 50%: What's Going On? - NovaBay Pharmaceuticals (AMEX:NBY) - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 7 (M)
Shares Float 6 (M)
Held by Insiders 4.1 (%)
Held by Institutions 3.9 (%)
Shares Short 33 (K)
Shares Short P.Month 93 (K)
Stock Financials
EPS -7.06
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.76
Profit Margin -93.9 %
Operating Margin -34.2 %
Return on Assets (ttm) -24.5 %
Return on Equity (ttm) -132 %
Qtrly Rev. Growth -14.7 %
Gross Profit (p.s.) 0
Sales Per Share 2.24
EBITDA (p.s.) -1.02
Qtrly Earnings Growth 0 %
Operating Cash Flow -5 (M)
Levered Free Cash Flow -1 (M)
Stock Valuations
PE Ratio -0.37
PEG Ratio 0
Price to Book value 3.33
Price to Sales 1.14
Price to Cash Flow -3.34
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android